159 related articles for article (PubMed ID: 37978114)
1. Nationwide Analysis of Locoregional Management for Ductal Carcinoma In Situ in Males: An NCDB Analysis of the Surgical Approach to DCIS in Males.
Carter MM; Whitrock JN; Pratt CG; Shaughnessy EA; Meier TM; Barrord MF; Hanseman DJ; Reyna CR; Heelan AA; Lewis JD
Ann Surg Oncol; 2024 Mar; 31(3):1599-1607. PubMed ID: 37978114
[TBL] [Abstract][Full Text] [Related]
2. Patterns of Care and Utilization of Radiation for Women With Good-Risk Ductal Carcinoma In Situ: A National Cancer Database Analysis.
Silver B; Mattessich S; Yacoub I; Rhee B; Schreiber D
Cureus; 2022 Aug; 14(8):e28223. PubMed ID: 36158412
[TBL] [Abstract][Full Text] [Related]
3. Patterns of care analysis among women with ductal carcinoma in situ in North Carolina.
Jackson LC; Camacho F; Levine EA; Anderson RT; Stewart JH
Am J Surg; 2008 Feb; 195(2):164-9. PubMed ID: 18096124
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of Microinvasive Ductal Carcinoma In Situ Versus Noninvasive and Invasive Breast Cancer.
Strang LR; Sun J; Sun W; Boulware D; Kiluk JV; Lee MC; Khazai L; Laronga C
J Surg Res; 2020 Oct; 254():378-383. PubMed ID: 32535256
[TBL] [Abstract][Full Text] [Related]
5. Locoregional Control Benefit of a Tumor Bed Boost for Ductal Carcinoma In Situ.
Dreyfuss AD; Max D; Flynn J; Zhang Z; Gillespie EF; Xu A; Cuaron J; Mueller B; Khan AJ; Cahlon O; Powell SN; McCormick B; Braunstein LZ
Adv Radiat Oncol; 2023; 8(5):101254. PubMed ID: 37250283
[TBL] [Abstract][Full Text] [Related]
6. Factors Influencing Use of Hormone Therapy for Ductal Carcinoma In Situ: A National Cancer Database Study.
Nguyen TT; Hoskin TL; Day CN; Habermann EB; Goetz MP; Boughey JC
Ann Surg Oncol; 2017 Oct; 24(10):2989-2998. PubMed ID: 28766214
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic Features, Treatment Patterns, and Disease Outcomes in a Modern, Prospective Cohort of Young Women Diagnosed with Ductal Carcinoma In Situ.
Tesch ME; Rosenberg SM; Collins LC; Wong JS; Dominici L; Ruddy KJ; Tamimi R; Schapira L; Borges VF; Warner E; Come SE; Partridge AH
Ann Surg Oncol; 2022 Dec; 29(13):8048-8057. PubMed ID: 35960452
[TBL] [Abstract][Full Text] [Related]
8. Ductal carcinoma in situ in patients younger than 30 years: differences in adjuvant endocrine therapy and outcomes.
Halasz SR; O'Keefe T; Wallace AM; Blair SL
Breast Cancer Res Treat; 2021 Apr; 186(2):551-559. PubMed ID: 33180236
[TBL] [Abstract][Full Text] [Related]
9. Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ.
Worni M; Akushevich I; Greenup R; Sarma D; Ryser MD; Myers ER; Hwang ES
J Natl Cancer Inst; 2015 Dec; 107(12):djv263. PubMed ID: 26424776
[TBL] [Abstract][Full Text] [Related]
10. Trends in adjuvant therapies after breast-conserving surgery for hormone receptor-positive ductal carcinoma in situ: findings from the National Cancer Database, 2004-2013.
Sagara Y; Freedman RA; Wong SM; Aydogan F; Nguyen A; Barry WT; Golshan M
Breast Cancer Res Treat; 2017 Nov; 166(2):583-592. PubMed ID: 28776282
[TBL] [Abstract][Full Text] [Related]
11. Trends in Unilateral and Contralateral Prophylactic Mastectomy Use in Ductal Carcinoma In Situ of the Breast: Patterns and Predictors.
Zhang B; Coopey SB; Gadd MA; Hughes KS; Chang DC; Oseni TO
Ann Surg Oncol; 2019 Nov; 26(12):3863-3873. PubMed ID: 31325048
[TBL] [Abstract][Full Text] [Related]
12. The role of MRI and clinicopathologic features in predicting the invasive component of biopsy-confirmed ductal carcinoma in situ.
Yoon GY; Choi WJ; Cha JH; Shin HJ; Chae EY; Kim HH
BMC Med Imaging; 2020 Aug; 20(1):95. PubMed ID: 32787871
[TBL] [Abstract][Full Text] [Related]
13. Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis.
Boyages J; Delaney G; Taylor R
Cancer; 1999 Feb; 85(3):616-28. PubMed ID: 10091735
[TBL] [Abstract][Full Text] [Related]
14. [Surgical treatment and prognosis of ductal carcinoma in situ: 526 cases analysis].
Zhu SJ; Chen XS; Wu JY; Huang O; He JR; Zhu L; Chen WG; Li YF; Fei XC; Shen KW
Zhonghua Wai Ke Za Zhi; 2017 Feb; 55(2):114-119. PubMed ID: 28162210
[No Abstract] [Full Text] [Related]
15. Treating Second Breast Events After Breast-Conserving Surgery for Ductal Carcinoma in Situ.
Hassett MJ; Jiang W; Hughes ME; Edge S; Javid SH; Niland JC; Theriault R; Wong YN; Schrag D; Punglia RS
J Natl Compr Canc Netw; 2018 Apr; 16(4):387-394. PubMed ID: 29632058
[No Abstract] [Full Text] [Related]
16. Use of the Twelve-Gene Recurrence Score for Ductal Carcinoma in Situ and Its Influence on Receipt of Adjuvant Radiation and Hormonal Therapy.
Piltin MA; Hoskin TL; Day CN; Shumway DA; Habermann EB; Davis J; Boughey JC
Ann Surg Oncol; 2021 Aug; 28(8):4294-4303. PubMed ID: 33462716
[TBL] [Abstract][Full Text] [Related]
17. Ductal carcinoma in situ on core needle biopsy only with no residual disease at surgery.
Dubrovsky E; Nguyen P; Chun J; Schwartz S; Raymond S; Guth A; Schnabel F; Gerber NK
Breast J; 2018 Nov; 24(6):971-975. PubMed ID: 30062749
[TBL] [Abstract][Full Text] [Related]
18. Association of Radiotherapy With Survival in Women Treated for Ductal Carcinoma In Situ With Lumpectomy or Mastectomy.
Giannakeas V; Sopik V; Narod SA
JAMA Netw Open; 2018 Aug; 1(4):e181100. PubMed ID: 30646103
[TBL] [Abstract][Full Text] [Related]
19. The management of ductal carcinoma in situ (DCIS). The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Canadian Association of Radiation Oncologists.
CMAJ; 1998 Feb; 158 Suppl 3():S27-34. PubMed ID: 9484276
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of ductal carcinoma in situ component in invasive ductal carcinoma of the breast: a Surveillance, Epidemiology, and End Results database analysis.
Wu SG; Zhang WW; Sun JY; He ZY
Cancer Manag Res; 2018; 10():527-534. PubMed ID: 29593431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
